nach oben

Erschienen in:

01.03.2012 | Experimental research

Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic Moyamoya angiopathy

verfasst von: Markus Kraemer, Peter A. Horn, Constantin Roder, Nadia Khan, Rolf R. Diehl, Peter Berlit, Falko M. Heinemann

Erschienen in: Acta Neurochirurgica | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

The etiology and genetic susceptibility of Moyamoya angiopathy (MMA) (Moyamoya disease, Moyamoya syndrome and unilateral type of MMA) still remain unclear. In Asian patient cohorts several HLA markers were described to be associated with MMA, but in Caucasians very little is known about genetic susceptibility of this angiopathy.

Method

We analysed DNA of 33 Caucasian patients with MMA for HLA-A, HLA-B, HLA-DRB1, and HLA-DQB1 markers, respectively. HLA frequencies of all 33 patients with MMA were compared with HLA-frequencies of Caucasian controls. Additionally, subgroup analysis of 22 patients with Moyamoya disease (MMD) and 11 patients with unilateral type of MMA was performed.

Findings

Significant association was observed for HLA-DRB1*03 and HLA-DRB1*13 in all 33 patients (P _c < 0.001 and P _c < 0.001, respectively). Moreover, HLA-A*02 (P _c = 0.009); HLA-B*08 (P _c = 0.009), and HLA-DQB1*03 (P _c = 0.003) frequencies were higher in all patients with MMA when compared with the controls. In addition, in 22 patients with MMD a higher frequency of HLA-DRB1*03 (P _c < 0.001) was observed when compared with controls.

Conclusions

The results of this study indicate a putative association of HLA markers with MMA in Caucasian patients. Further studies are needed to elucidate the role of human MHC in the pathogenesis of this angiopathy.

Achrol AS, Guzman R, Lee M, Steinberg GK (2009) Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus 26:E4PubMedCrossRef

Andreone V, Ciarmiello A, Fusco C, Ambrosanio G, Florio C, Linfante I (1999) Moyamoya disease in Italian monozygotic twins. Neurology 53:1332–1335PubMed

Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, Yamamoto K (1995) Human leukocyte antigen in patients with moyamoya disease. Stroke 26:415–417PubMedCrossRef

Bax M, van Heemst J, Huizinga TW, Toes RE (2011) Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 63:459–466PubMedCrossRef

Chessman D, Kostenko L, Lethborg T, Purcell AW, Williamson NA, Chen Z, Kjer-Nielsen L, Mifsud NA, Tait BD, Holdsworth R, Almeida CA, Nolan D, Macdonald WA, Archbold JK, Kellerher AD, Marriott D, Mallal S, Bharadwaj M, Rossjohn J, McCluskey J (2008) Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 28:822–832PubMedCrossRef

Fukui M (1997) Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis (‘moyamoya’ disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan. Clin Neurol Neurosurg 99(Suppl 2):S238–S240PubMed

Goyal MS, Hallemeier CL, Zipfel GJ, Rich KM, Grubb RL Jr, Chicoine MR, Moran CJ, Cross DT 3rd, Dacey RG Jr, Derdeyn CP (2010) Clinical features and outcome in North American adults with idiopathic basal arterial occlusive disease without moyamoya collaterals. Neurosurgery 67:278–285PubMedCrossRef

Guo DC, Papke CL, Tran-Fadulu V, Regalado ES, Avidan N, Johnson RJ, Kim DH, Pannu H, Willing MC, Sparks E, Pyeritz RE, Singh MN, Dalman RL, Grotta JC, Marian AJ, Boerwinkle EA, Frazier LQ, LeMaire SA, Coselli JS, Estrera AL, Safi HJ, Veeraraghavan S, Muzny DM, Wheeler DA, Willerson JT, Yu RK, Shete SS, Scherer SE, Raman CS, Buja LM, Milewicz DM (2009) Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. Am J Hum Genet 84:617–627PubMedCrossRef

Han H, Pyo CW, Yoo DS, Huh PW, Cho KS, Kim DS (2003) Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population. J Korean Med Sci 18:876–880PubMed

10.

Heinemann FM (2009) HLA genotyping and antibody characterization using the Luminex multiplex technology. Transfus Med Hemother 36:273–278PubMedCrossRef

11.

Herve D, Touraine P, Verloes A, Miskinyte S, Krivosic V, Logeart D, Alili N, Laredo JD, Gaudric A, Houdart E, Metzger JP, Tournier-Lasserve E, Woimant F (2010) A hereditary moyamoya syndrome with multisystemic manifestations. Neurology 75:259–264PubMedCrossRef

12.

Hong SH, Wang KC, Kim SK, Cho BK, Park MH (2009) Association of HLA-DR and -DQ genes with familial Moyamoya disease in Koreans. J Korean Neurosurg Soc 46:558–563PubMedCrossRef

13.

Houkin K, Abe H, Yoshimoto T, Takahashi A (1996) Is "unilateral" moyamoya disease different from moyamoya disease? J Neurosurg 85:772–776PubMedCrossRef

14.

Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T (1999) Mapping of a familial moyamoya disease gene to chromosome 3p24.2-p26. Am J Hum Genet 64:533–537PubMedCrossRef

15.

Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M (2000) Linkage analysis of moyamoya disease on chromosome 6. J Child Neurol 15:179–182PubMedCrossRef

16.

Inoue TK, Ikezaki K, Sasazuki T, Ono T, Kamikawaji N, Matsushima T, Fukui M (1997) DNA typing of HLA in the patients with moyamoya disease. Jpn J Hum Genet 42:507–515PubMedCrossRef

17.

Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, Kanno J, Niihori T, Ono M, Ishii N, Owada Y, Fujimura M, Mashimo Y, Suzuki Y, Hata A, Tsuchiya S, Tominaga T, Matsubara Y, Kure S (2011) A genome-wide association study identifies RNF213 as the first Moyamoya disease gene. J Hum Genet 56:34–40PubMedCrossRef

18.

Khan N, Schuknecht B, Boltshauser E, Capone A, Buck A, Imhof HG, Yonekawa Y (2003) Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien) 145:1061–1071, discussion 1071CrossRef

19.

Kim SJ, Heo KG, Shin HY, Bang OY, Kim GM, Chung CS, Kim KH, Jeon P, Kim JS, Hong SC, Lee KH (2010) Association of thyroid autoantibodies with moyamoya-type cerebrovascular disease: a prospective study. Stroke 41:173–176PubMedCrossRef

20.

Kitahara T, Okumura K, Semba A, Yamaura A, Makino H (1982) Genetic and immunologic analysis on moya-moya. J Neurol Neurosurg Psychiatry 45:1048–1052PubMedCrossRef

21.

Kraemer M, Berlit P (2010) Primary central nervous system vasculitis and moyamoya disease: similarities and differences. J Neurol 257:816–819PubMedCrossRef

22.

Kraemer M, Berlit P, Diesner F, Khan N (2011) What is the expert’s option on antiplatelet therapy in moyamoya disease? Results of a worldwide Survey. Eur J Neurol. doi:10.1111/j.1468-1331.2011.03481.x

23.

Kraemer M, Heienbrok W, Berlit P (2008) Moyamoya disease in Europeans. Stroke 39:3193–3200PubMedCrossRef

24.

Kraemer MHF, Horn P, Venker C, Berlit P, Krischek B, Khan N (2011) Inheritance of Moyamoya disease in a Caucasian familiy. Eur J Neurol. doi:10.1111/j.1468-1331.2011.03536.x

25.

Kramer M, Berlit P (2010) [Moyamoya disease - a rare vasculopathy in Europeans]. Fortschr Neurol Psychiatr 78:542–550, quiz 551PubMedCrossRef

26.

Krischek B, Kasuya H, Khan N, Tatagiba M, Roder C, Kraemer M (2011) Genetic and clinical characteristics of Moyamoya disease in Europeans. Acta neurochirurgica Supplement 112

27.

Li H, Zhang ZS, Dong ZN, Ma MJ, Yang WZ, Han C, Du MM, Liu YX, Yang H, Liu W, Duan L, Cao WC (2011) Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case–control study. Stroke 42:1138–1139PubMedCrossRef

28.

Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, Kikuta K, Takagi Y, Harada KH, Fujiyama A, Herzig R, Krischek B, Zou L, Kim JE, Kitakaze M, Miyamoto S, Nagata K, Hashimoto N, Koizumi A (2011) Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6:e22542PubMedCrossRef

29.

Maiers M, Gragert L, Klitz W (2007) High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 68:779–788PubMedCrossRef

30.

Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT (2002) Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727–732PubMedCrossRef

31.

Martorana D, Vaglio A, Greco P, Zanetti A, Moroni G, Salvarani C, Savi M, Buzio C, Neri TM (2006) Chronic periaortitis and HLA-DRB1*03: another clue to an autoimmune origin. Arthritis Rheum 55:126–130PubMedCrossRef

32.

Milewicz DM, Ostergaard JR, Ala-Kokko LM, Khan N, Grange DK, Mendoza-Londono R, Bradley TJ, Olney AH, Ades L, Maher JF, Guo D, Buja LM, Kim D, Hyland JC, Regalado ES (2010) De novo ACTA2 mutation causes a novel syndrome of multisystemic smooth muscle dysfunction. Am J Med Genet A 152A:2437–2443PubMedCrossRef

33.

Mineharu Y, Liu W, Inoue K, Matsuura N, Inoue S, Takenaka K, Ikeda H, Houkin K, Takagi Y, Kikuta K, Nozaki K, Hashimoto N, Koizumi A (2008) Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology 70:2357–2363PubMedCrossRef

34.

Mineharu Y, Takenaka K, Yamakawa H, Inoue K, Ikeda H, Kikuta KI, Takagi Y, Nozaki K, Hashimoto N, Koizumi A (2006) Inheritance pattern of familial moyamoya disease: autosomal dominant mode and genomic imprinting. J Neurol Neurosurg Psychiatry 77:1025–1029PubMedCrossRef

35.

Miskinyte S, Butler MG, Herve D, Sarret C, Nicolino M, Petralia JD, Bergametti F, Arnould M, Pham VN, Gore AV, Spengos K, Gazal S, Woimant F, Steinberg GK, Weinstein BM, Tournier-Lasserve E (2011) Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am J Hum Genet 88:718–728PubMedCrossRef

36.

Muller CR, Ehninger G, Goldmann SF (2003) Gene and haplotype frequencies for the loci hLA-A, hLA-B, and hLA-DR based on over 13,000 german blood donors. Hum Immunol 64:137–151PubMedCrossRef

37.

Oudshoorn M, Horn PA, Tilanus M, Yu N (2007) Typing of potential and selected donors for transplant: methodology and resolution. Tissue Antigens 69(Suppl 1):10–12PubMedCrossRef

38.

Park MH, Hong SH, Wang K-C (2010) HLA studies in Moyamoya disease. In: Cho BK, Tominaga T (eds) Moyamoya disease update. Springer, New York, pp 54–60CrossRef

39.

Parums DV, Brown DL, Mitchinson MJ (1990) Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114:383–387PubMed

40.

Parums DV, Dunn DC, Dixon AK, Mitchinson MJ (1990) Characterization of inflammatory cells in a patient with chronic periaortitis. Am J Cardiovasc Pathol 3:121–129PubMed

41.

Roder C, Nayak NR, Khan N, Tatagiba M, Inoue I, Krischek B (2010) Genetics of moyamoya disease. J Hum Genet 55:711–716PubMedCrossRef

42.

Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B (2010) Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochir (Wien) 152:2153–2160CrossRef

43.

Roder C, Peters V, Kasuya H, Nishizawa T, Takehara Y, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B (2011) Common genetic polymorphisms in moyamoya and atherosclerotic disease in Europeans. Childs Nerv Syst 27:245–252PubMedCrossRef

44.

Roder C, Peters V, Kasuya H, Nishizawa T, Wakita S, Berg D, Schulte C, Khan N, Tatagiba M, Krischek B (2011) Analysis of ACTA2 in European Moyamoya disease patients. Eur J Paediatr Neurol 15:117–122PubMedCrossRef

45.

Sakurai K, Horiuchi Y, Ikeda H, Ikezaki K, Yoshimoto T, Fukui M, Arinami T (2004) A novel susceptibility locus for moyamoya disease on chromosome 8q23. J Hum Genet 49:278–281PubMedCrossRef

46.

Takagi Y (2010) Vascular smooth muscle cell-related molecules and cells. In: Cho BK, Tominaga T (eds) Moyamoya disease update. Spinger, Heidelberg, pp 69–72CrossRef

47.

Takagi Y, Kikuta K, Nozaki K, Hashimoto N (2007) Histological features of middle cerebral arteries from patients treated for Moyamoya disease. Neurol Med Chir (Tokyo) 47:1–4CrossRef

48.

Yamamoto M, Aoyagi M, Tajima S, Wachi H, Fukai N, Matsushima Y, Yamamoto K (1997) Increase in elastin gene expression and protein synthesis in arterial smooth muscle cells derived from patients with Moyamoya disease. Stroke 28:1733–1738PubMedCrossRef

49.

Yamauchi T, Tada M, Houkin K, Tanaka T, Nakamura Y, Kuroda S, Abe H, Inoue T, Ikezaki K, Matsushima T, Fukui M (2000) Linkage of familial moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25. Stroke 31:930–935PubMedCrossRef

50.

Yonekawa Y, Fandimo J, Hug M, Wiesli M, Fujioka M, Khan N (2010) Moyamoya angiopathy in Europe. In: Cho BK, Tominaga T (eds) Moyamoya disease update. Springer, New York

51.

Yonekawa Y, Khan N (2003) Moyamoya disease. Adv Neurol 92:113–118PubMed

52.

Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG (1997) Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 99(Suppl 2):S58–S60PubMedCrossRef

Titel: Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic Moyamoya angiopathy
verfasst von: Markus Kraemer
Peter A. Horn
Constantin Roder
Nadia Khan
Rolf R. Diehl
Peter Berlit
Falko M. Heinemann
Publikationsdatum: 01.03.2012
Verlag: Springer Vienna
Erschienen in: Acta Neurochirurgica / Ausgabe 3/2012
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI: https://doi.org/10.1007/s00701-011-1261-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Analysis of human leucocyte antigen genes in Caucasian patients with idiopathic Moyamoya angiopathy

Abstract

Background

Method

Findings

Conclusions

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Background

Method

Findings

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2012

The impact of general versus local anesthesia on early subclinical cognitive function following carotid endarterectomy evaluated using P3 event-related potentials

Verbal memory capacity after treatment for ruptured intracranial aneurysm—the outcomes of three psychological tests: within a month, 1 year after and 5-7 years after treatment

Direct arteriovenous fistula at the inferolateral trunk mimicking carotid cavernous fistula without involving the cavernous sinus: a case report

Complex arteriovenous fistulas at C1 causing hematomyelia through aneurysmal rupture of a feeder from the anterior spinal artery

Assessment of non-motor hearing symptoms in hemifacial spasm using magnetoencephalography

Single stage gamma knife radiosurgical treatment of large AVMs

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie